Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALVAC-HIV vCP1452
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
ALVAC-HIV vCP1452 is a recombinant canarypox-based (ALVAC) viral vector vaccine developed by Sanofi Pasteur for the prevention and treatment of HIV-1 infection. The vaccine utilizes a modified, replication-incompetent canarypox virus to express several HIV-1 antigens, including the envelope gp120 (MN strain) fused to the transmembrane portion of gp41 (LAI strain), the full-length Gag protein (LAI strain), and specific protease and CTL epitope sequences from the Pol and Nef regions. Additionally, the vector incorporates vaccinia virus-derived E3L and K3L genes to enhance protein expression and prevent host-cell apoptosis, thereby improving immunogenicity. Primarily designed to elicit or boost CD8+ T-cell responses, vCP1452 has been evaluated in Phase I and II clinical trials as a standalone agent and as part of prime-boost strategies involving protein subunits like AIDSVAX B/E.
- Brand names
- ALVAC-HIV
- Other names
- ALVAC-HIV (vCP1452)
02
Targets
Gag (HIV-1 Gag polyprotein)HIV-1 Nef cytotoxic T lymphocyte epitopesPol (HIV-1 Pol polyprotein)Nef (HIV-1 Nef)Human immunodeficiency virus type 1 reverse transcriptaseEnv (HIV-1 envelope glycoprotein)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on ALVAC-HIV vCP1452.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALVAC-HIV vCP1452.